Predicting High-Flow Nasal Cannula Failure in Acute Hypoxemic Respiratory Failure Using Metabolomics and Clinical Data
Metabolomics and Clinical Data to Predict High-Flow Nasal Cannula Failure and Optimize Respiratory Support in Acute Hypoxemic Respiratory Failure
Hospital del Mar Research Institute (IMIM)
300 participants
Jun 4, 2026
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are: Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes? Participants will: Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.
Eligibility
Inclusion Criteria5
- Adult patients (≥18 years old).
- Admission to the intensive care unit (ICU) with acute hypoxemic respiratory failure (AHRF).
- Treatment with high-flow nasal cannula (HFNC) as the initial respiratory support strategy.
- Inclusion within the first 24 hours after HFNC initiation.
- Provision of informed consent by the patient or legally authorized representative.
Exclusion Criteria4
- Age <18 years.
- Active do-not-resuscitate (DNR) orders or limitation of therapeutic effort.
- Refusal or inability to provide informed consent.
- Previous invasive mechanical ventilation before study inclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07607080